Crescentic glomerulonephritis: An update on pauci-immune and anti-GBM diseases

Advances in Anatomic Pathology

Volumn 19, Issue 2, 2012, Pages 111-124

  Kambham, Neeraja ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ANCA; anti GBM; crescentic glomerulonephritis; pauci immune

Indexed keywords

AZATHIOPRINE; COLLAGEN TYPE 4; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN G; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ANTI GLOMERULUS BASEMENT MEMBRANE GLOMERULONEPHRITIS; CELL THERAPY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; ELECTRON MICROSCOPY; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS BASEMENT MEMBRANE; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN DEPOSITION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; NONHUMAN; PATHOGENESIS; PAUCI IMMUNE GLOMERULONEPHRITIS; PLASMAPHERESIS; PRIORITY JOURNAL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW;

AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS; HUMANS;

EID: 84857303864     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e318248b7a1     Document Type: Review

References (97)

1. Thorner PS, Ho M, Eremina V, et al. Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol. 2008;19:495-502. (Pubitemid 351355393)
2. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63:1164-1177. (Pubitemid 36315601)
3. Association of Directors of Anatomic and Surgical Pathology. Critical diagnoses (critical values) in anatomic pathology. Am J Surg Pathol. 2006;30:897-899.
4. Nakhleh RE, Myer JL, Allen TC, et al. Consensus statement on effective communication of urgent diagnoses and significant, unexpected diagnoses in surgical pathology and cyto-pathology from the College of American Pathologists and Association of Directors of Anatomic and Surgical Pathology. Arch Pathol Lab Med. 2011;135:1-7.
5. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337:1512-1523. (Pubitemid 27495778)
6. Bomback AS, Appel GB, Radhakrishnan J, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2010.
7. Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. Am J Kidney Dis. 1994;24:130-141. (Pubitemid 24212988)
8. Savige J, Davies D, Falk RJ, et al. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int. 2000;57:846-862. (Pubitemid 30434775)
9. Falk RJ, Jennette JC. ANCA disease: where is this field heading? J Am Soc Nephrol. 2010;21:745-752.
10. Jennette JCTD. Pauci-immune and antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis and vas-culitis. In: Jennette JCOJ, Schwartz MM, Silva FG, eds. Pathology of the Kidney. Philadelphia: Lippincott Williams & Wilkins; 2007:664-673.
11. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004;117:39-50. (Pubitemid 38798019)
12. Holle JU, Laudien M, Gross WL. Clinical manifestations and treatment of Wegener's granulomatosis. Rheum Dis Clin North Am. 2010;36:507-526.
13. Davies DJ, Moran JE, Niall JF, et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed). 1982;285:606. (Pubitemid 12042688)
14. Lionaki S, Jennette JC, Falk RJ. Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomeruloneph-ritis. Semin Immunopathol. 2007;29:459-474. (Pubitemid 350077264)
15. Morgan MD, Harper L, Williams J, et al. Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol. 2006;17:1224-1234. (Pubitemid 43673402)
16. Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol. 2005;19:263-276. (Pubitemid 40568179)
17. Gaffo AL. Diagnostic approach to ANCA-associated vasculi-tides. Rheum Dis Clin North Am. 2010;36:491-506.
18. Savige J, Gillis D, Benson E, et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999; 111:507-513. (Pubitemid 29153147)
19. Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int. 1998;53:796-798.
20. Rutgers A, Sanders JS, Stegeman CA, et al. Pauci-immune necrotizing glomerulonephritis. Rheum Dis Clin North Am. 2010;36:559-572.
21. Schnabel A, Holl-Ulrich K, Dalhoff K, et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J. 1997;10:2738-2743. (Pubitemid 28052780)
22. Hauer HA, Bajema IM, van Houwelingen HC, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002;61:80-89. (Pubitemid 34075133)
23. Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis. 2006;47: 770-779.
24. Vizjak A, Rott T, Koselj-Kajtna M, et al. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis. 2003;41:539-549. (Pubitemid 36278370)
25. Bonsib SM, Goeken JA, Fandel T, et al. Necrotizing medullary lesions in patients with ANCA associated renal disease. Mod Pathol. 1994;7:181-185.
26. Neumann I, Regele H, Kain R, et al. Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis. Nephrol Dial Transplant. 2003;18:524-531. (Pubitemid 36305657)
27. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628-1636.
28. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulo-nephritis and vasculitis in mice. J Clin Invest. 2002;110: 955-963.
29. Kallenberg CG. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun. 2008;30:29-36.
30. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170: 52-64. (Pubitemid 47339189)
31. Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med. 2008;14:1088-1096.
32. Roth AJ, Brown MC, Smith RN, et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol. 2011.
33. Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008;19:2421-2429.
34. Bell EK, Chugh SS, Cook WJ. A case of infection-associated antiproteinase-3-negative cytoplasmic antineutrophil cytoplas-mic antibody pauci-immune focal necrotizing glomeruloneph-ritis. Nephrol Dial Transplant. 2010;25:3119-3123.
35. Stegeman CA, Tervaert JW, de Jong PE, et al. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335:16-20. (Pubitemid 26230808)
36. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med. 1994;120:12-17. (Pubitemid 24011495)
37. Tidman M, Olander R, Svalander C, et al. Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med. 1998;244: 133-141. (Pubitemid 28364798)
38. Summers SA, van der Veen BS, O'Sullivan KM, et al. Intrinsic renal cell and leukocyte-derived TLR4 aggravate experimental anti-MPO glomerulonephritis. Kidney Int. 2011;78:1263-1274.
39. Bosch X. LAMPs and NETs in the pathogenesis of ANCA vasculitis. J Am Soc Nephrol. 2009;20:1654-1656.
40. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532-1535. (Pubitemid 38314426)
41. Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15:623-625.
42. Pendergraft WF III, Preston GA, Shah RR, et al. Auto-immunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med. 2004;10:72-79. (Pubitemid 38524701)
43. Pendergraft WF III, Pressler BM, Jennette JC, et al. Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med. 2005;83:12-25. (Pubitemid 40169492)
44. Tadema H, Kallenberg CG, Stegeman CA, et al. Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis. PLoS One. 2011;6:e17972.
45. Gao Y, Zhao MH. Review article: drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Neph-rology (Carlton). 2009;14:33-41.
46. Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol. 2008; 20:35-39. (Pubitemid 351339430)
47. Kanda T, Tanio H, Wu C, et al. Churg-Strauss syndrome with severe granulomatous angiitis and crescentic glomeruloneph-ritis, which developed during therapy with a leukotriene receptor antagonist. Clin Exp Nephrol. 2010;14:602-607.
48. Hirohama D, Hoshino J, Hasegawa E, et al. Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-alpha. Mod Rheumatol. 2010;20: 602-605.
49. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400-1406. (Pubitemid 41430613)
50. Borgmann S, Haubitz M. Genetic impact of pathogenesis and prognosis of ANCA-associated vasculitides. Clin Exp Rheu-matol. 2004;22:S79-S86.
51. Ciavatta DJ, Yang J, Preston GA, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest. 2010;120:3209-3219.
52. Lepse N, Abdulahad WH, Kallenberg CG, et al. Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev. 2011.
53. Rimbert M, Hamidou M, Braudeau C, et al. Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One. 2011;6:e18734.
54. Gan PY, Steinmetz OM, Tan DS, et al. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol. 2010;21:925-931.
55. Ooi JD, Kitching AR, Holdsworth SR. Review: T helper 17 cells: their role in glomerulonephritis. Nephrology (Carlton). 2010;15:513-521.
56. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143:621-631.
57. Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-2918.
58. Little MA, Hassan B, Jacques S, et al. Renal transplantation in systemic vasculitis: when is it safe? Nephrol Dial Transplant. 2009;24:3219-3225.
59. Geetha D, Seo P. Renal transplantation in the ANCA-associated vasculitides. Am J Transplant. 2007;7:2657-2662. (Pubitemid 350045766)
60. Nachman PH, Segelmark M, Westman K, et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int. 1999;56:1544-1550. (Pubitemid 29451261)
61. Moroni G, Torri A, Gallelli B, et al. The long-term prognosis of renal transplant in patients with systemic vasculitis. Am J Transplant. 2007;7:2133-2139. (Pubitemid 47247051)
62. Daly C, Conlon PJ, Medwar W, et al. Characteristics and outcome of anti-glomerular basement membrane disease: a single-center experience. Ren Fail. 1996;18:105-112. (Pubitemid 26073879)
63. Bolton WK. Goodpasture's syndrome. Kidney Int. 1996;50: 1753-1766. (Pubitemid 26364285)
64. Saraf P, Berger HW, Thung SN. Goodpasture's syndrome with no overt renal disease. Mt Sinai J Med. 1978;45:451-454. (Pubitemid 9039098)
65. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973;3:74-89.
66. Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am J Ind Med. 1992;21:141-153.
67. Proskey AJ, Weatherbee L, Easterling RE, et al. Good-pasture's syndrome. A report of five cases and review of the literature. Am J Med. 1970;48:162-173.
68. Cui Z, Zhao J, Jia XY, et al. Clinical features and outcomes of anti-glomerular basement membrane disease in older patients. Am J Kidney Dis. 2011;57:575-582.
69. Cui Z, Zhao MH, Singh AK, et al. Antiglomerular basement membrane disease with normal renal function. Kidney Int. 2007;72:1403-1408. (Pubitemid 350126772)
70. Yang R, Hellmark T, Zhao J, et al. Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease. Nephrol Dial Transplant. 2009;24:1838-1844.
71. Hellmark T, Segelmark M, Unger C, et al. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int. 1999;55:936-944. (Pubitemid 29100705)
72. Salama AD, Dougan T, Levy JB, et al. Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis. 2002;39:1162-1167. (Pubitemid 34591930)
73. Saxena R, Bygren P, Cederholm B, et al. Circulating anti-entactin antibodies in patients with glomerulonephritis. Kidney Int. 1991;39:996-1004.
74. Saxena R, Bygren P, Rasmussen N, et al. Circulating autoantibodies in patients with extracapillary glomeruloneph-ritis. Nephrol Dial Transplant. 1991;6:389-397.
75. Border WA, Baehler RW, Bhathena D, et al. IgA antibasement membrane nephritis with pulmonary hemorrhage. Ann Intern Med. 1979;91:21-25. (Pubitemid 9244628)
76. Ho J, Gibson IW, Zacharias J, et al. Antigenic heterogeneity of IgA anti-GBM disease: new renal targets of IgA autoanti-bodies. Am J Kidney Dis. 2008;52:761-765.
77. Shaer AJ, Stewart LR, Cheek DE, et al. IgA antiglomerular basement membrane nephritis associated with Crohn's disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis. 2003;41:1097-1109. (Pubitemid 36532145)
78. Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967;126:989-1004.
79. Germuth FG Jr., Choi IJ, Taylor JJ, et al. Antibasement membrane disease. I. The glomerular lesions of Goodpasture's disease and experimental disease in sheep. Johns Hopkins Med J. 1972;131:367-384.
80. Ohnuki T. Crescentic glomerulonephritis induced in the goat by immunization with homologous or heterologous glomerular basement membrane antigen. Acta Pathol Jpn. 1975;25:319-331.
81. Huey B, McCormick K, Capper J, et al. Associations of HLA-DR and HLA-DQ types with anti-GBM nephritis by sequence-specific oligonucleotide probe hybridization. Kidney Int. 1993; 44:307-312. (Pubitemid 23228684)
82. Yang R, Cui Z, Zhao J, et al. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin Immunol. 2009;133:245-250.
83. Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med. 2010;363:343-354.
84. Cashman SJ, Pusey CD, Evans DJ. Extraglomerular distribution of immunoreactive Goodpasture antigen. J Pathol. 1988;155:61-70.
85. Salant DJ. Goodpasture's disease-new secrets revealed. N Engl J Med. 2010;363:388-391.
86. Borza DB, Neilson EG, Hudson BG. Pathogenesis of Goodpasture syndrome: a molecular perspective. Semin Nephrol. 2003;23:522-531. (Pubitemid 38030086)
87. Bolton WK, Innes DJ Jr., Sturgill BC, et al. T-cells and macrophages in rapidly progressive glomerulonephritis: clin-icopathologic correlations. Kidney Int. 1987;32:869-876. (Pubitemid 18015518)
88. Bosch X, Mirapeix E, Font J, et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperox-idase specificity in anti-glomerular basement membrane disease. Clin Nephrol. 1991;36:107-113.
89. Clyne S, Frederick C, Arndt F, et al. Concurrent and discrete clinicopathological presentations of Wegener granulomatosis and anti-glomerular basement membrane disease. Am J Kidney Dis. 2009;54:1116-1120.
90. Rutgers A, Slot M, van Paassen P, et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperox-idase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46:253-262. (Pubitemid 41040353)
91. Hellmark T, Niles JL, Collins AB, et al. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol. 1997;8:376-385. (Pubitemid 127454173)
92. Peces R, Rodriguez M, Pobes A, et al. Sequential development of pulmonary hemorrhage with MPO-ANCA complicating anti-glomerular basement membrane antibody-mediated glo-merulonephritis. Am J Kidney Dis. 2000;35:954-957. (Pubitemid 30238211)
93. Cui Z, Zhao MH, Segelmark M, et al. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int. 2010;78:590-597.
94. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med. 2004;10:17-18. (Pubitemid 38524686)
95. Troxell ML, Saxena AB, Kambham N. Concurrent anti-glomerular basement membrane disease and membranous glomerulonephritis: a case report and literature review. Clin Nephrol. 2006;66:120-127. (Pubitemid 44219438)
96. Fukatsu A, Brentjens JR, Killen PD, et al. Studies on the formation of glomerular immune deposits in brown Norway rats injected with mercuric chloride. Clin Immunol Immuno-pathol. 1987;45:35-47. (Pubitemid 17133944)
97. Basford AW, Lewis J, Dwyer JP, et al. Membranous nephro-pathy with crescents. J Am Soc Nephrol. 2011:22:1804-1808.